Conflict of interest: Nothing to report.
Relapsed or refractory nongastric marginal zone B-cell lymphoma: Multicenter retrospective analysis of 92 cases†
Article first published online: 8 OCT 2009
Copyright © 2009 Wiley-Liss, Inc.
American Journal of Hematology
Volume 84, Issue 12, pages 826–829, December 2009
How to Cite
Oh, S. Y., Kim, W. S., Kim, S. J., Kim, J. S., Kim, S.-H., Lee, D. H., Won, J.-H., Hwang, I. G., Kim, M. K., Lee, S. I., Kim, J. G., Yang, D.-H., Kang, H. J., Choi, C. W., Park, J., Choi, Y. J., Kim, H. J., Kwon, J. H., Suh, C. and Kim, H.-J. (2009), Relapsed or refractory nongastric marginal zone B-cell lymphoma: Multicenter retrospective analysis of 92 cases. Am. J. Hematol., 84: 826–829. doi: 10.1002/ajh.21557
- Issue published online: 23 NOV 2009
- Article first published online: 8 OCT 2009
- Accepted manuscript online: 8 OCT 2009 12:00AM EST
- Manuscript Accepted: 30 SEP 2009
- Manuscript Revised: 11 SEP 2009
- Manuscript Received: 19 AUG 2009
- Korea Science and Engineering Foundation (KOSEF), Korea Government (MEST). Grant Number: R13-2002-044-05001-0
- Dong-A University Research Fund
Over its long survival duration, marginal zone B-cell lymphoma (MZL) routinely involves frequent relapses. In this study, we conducted a retrospective analysis to identify the clinical features and outcomes of relapsed or refractory MZL. From 1995 to 2008, a total of 92 patients with relapsed MZL were retrospectively analyzed. The median age of our subjects was 53.5 years (range: 23–82 years). The most common primary sites of involvement were the orbit and ocular adnexa (28.3%) followed by the lymph node and lymphatic organs (23.9%), and multiple mucosa-associated lymphoid tissue (MALT) sites (13.0%). The median time to relapse from initial diagnosis was 25.5 months. Of the 53 patients with Stage I or II at diagnosis, 42 patients (79.2%) evidenced locoregional recurrence. Among these locoregional relapsed patients, 27 patients achieved CR (54.1%) or PR (18.9%). In addition to the 39 patients initially in advanced Stage III or IV, a total of 50 patients were in advanced stage at relapse. Among those patients with advanced stage at relapse, 44 patients were treated. The overall response rate was 54.5% (24 patients), with 18 CRs and 6 PRs. The median time to progression (TTP) was 34.1 months (95% CI: 11.3–56.9 months) and the estimated 5-year overall survival (OS) was 84.3%. The majority of them was controlled well with salvage treatment, and could achieve prolonged survival. However, patients' refractory to initial therapy and advanced relapse evidenced shorter TTP and OS. Thus, we need to consider more aggressive treatment in cases of refractory MZL or advanced relapsed MZL. Am. J. Hematol., 2009. © 2009 Wiley-Liss, Inc.